NUVAXOVID, injectable dispersion. vaccine against COVID-19 (recombinant, with adjuvant) 100 doses
Active ingredients: PROTÉINE SPIKE (S) RECOMBINANTE DU SARS-COV-2
Commercialized according to BDPMDispensing in France: Prescription only
Injectable dispersion100 dosesintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- NUVAXOVID, dispersion injectable. Vaccin contre la COVID-19 (recombinant, avec adjuvant)
- Pharmaceutical form
- dispersion injectable
- Route of administration
- intramusculaire
- Presentation description
- 10 flacons multidoses en verre de 5 mL de 10 doses (100 doses)
- Marketing authorisation holder
- SANOFI WINTHROP INDUSTRIE
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 30 Nov 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
69544189CIP73024577CIP133400930245774Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PROTÉINE SPIKE (S) RECOMBINANTE DU SARS-COV-2dispersion | 5 microgrammes · une dose de 0,5 mL (un flacon contient 5 ou 10 doses) | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.